Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Price to Sales Ratio (P/S) on December 30, 2024: 56.64

Nyxoah S.A. Price to Sales Ratio (P/S) is 56.64 on December 30, 2024, a 70.03% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Nyxoah S.A. 52-week high Price to Sales Ratio (P/S) is 151.41 on March 18, 2024, which is 167.33% above the current Price to Sales Ratio (P/S).
Nyxoah S.A. 52-week low Price to Sales Ratio (P/S) is 31.29 on January 17, 2024, which is -44.75% below the current Price to Sales Ratio (P/S).
Nyxoah S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 69.54.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years